SCHEMBL2289650

SCHEMBL2289650

COc1ccc(Oc2ccc(C(=O)Nc3ccccc3C(=O)O)cc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 1/20 0.70
KMT2A Q03164 7/20 0.67
MEN1 O00255 6/20 0.67
NPC1 O15118 6/20 0.67
RAB9A P51151 5/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
MAPT P10636 2/20 0.65
CHEK1 O14757 1/20 0.64
PIM1 P11309 1/20 0.64
MAPK8 P45983 1/20 0.64
CLK4 Q9HAZ1 1/20 0.64
DHODH Q02127 1/20 0.62
NPSR1 Q6W5P4 2/20 0.62
PKM P14618 1/20 0.62
HDAC3 O15379 1/20 0.62
HDAC4 P56524 1/20 0.62
HDAC1 Q13547 1/20 0.62
HDAC7 Q8WUI4 1/20 0.62
HDAC2 Q92769 1/20 0.62
HDAC10 Q969S8 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14338416 0.96 F10 (0.77) F10KMT2AMEN1NPC1RAB9A
SCHEMBL14855681 0.93 F10 (0.72) F10KMT2AMEN1NPC1RAB9A
SCHEMBL30466712 0.93 MEN1 (0.72) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2025586 0.93 MEN1 (0.72) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2292518 0.91 SERPINE1 (0.71) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2293458 0.91 PGR (0.67) F10KMT2AMEN1NPC1RAB9A
SCHEMBL2291746 0.89 MEN1 (0.67) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL8027764 0.89 MEN1 (0.67) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2271007 0.88 MEN1 (0.69) F10KMT2AMEN1MAPTNPSR1
SCHEMBL2272706 0.86 MEN1 (0.67) F10KMT2AMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US claimed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US claimed
JP-2008546661-A 2008-12-25 JP claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US claimed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 F10 1535/4885KMT2A 1519/4885MEN1 1329/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 F10 1471/4885KMT2A 1557/4885MEN1 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.